Monitor for any subsequent analyst reports or price target changes from other firms; the initiation itself is a routine event for a publicly traded biotech and does not change the company's fundamentals or pipeline progress.
Price Chart
Executive Summary
Quantum BioPharma announced that Rodman & Renshaw initiated analyst coverage with a BUY rating and an $8 price target. The coverage is unpaid and the company provided no consideration. This is a positive but non-material event for a clinical-stage biotech with no approved products.
Key Facts
- Rodman & Renshaw initiated coverage with BUY rating and US$8 price target
- Coverage is unpaid and Quantum BioPharma provided no consideration
- Lead analyst is Michael G. King Jr., Director of Research, Senior Biotechnology Analyst
- Quantum retains 19.48% ownership of Unbuzzd as of June 30, 2026
- Unbuzzd royalty: 7% of sales until $250M, then 3% in perpetuity
Financial Impact
No financial impact from the coverage initiation itself; the $8 price target is an analyst opinion, not a company financial result.
Risk Factors
- Analyst coverage initiation does not guarantee future stock performance; price targets are opinions, not guarantees
- Clinical-stage biotech with no approved products; pipeline risk remains the primary driver of value
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-006084 |
| Exhibit: exh_991.htm | 0001171843-26-006084 |
| Document: 0001171843-26-006084-index-headers.html | 0001171843-26-006084 |
| Document: 0001171843-26-006084-index.html | 0001171843-26-006084 |
| Document: 0001171843-26-006084.txt | 0001171843-26-006084 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 6-K | $3.11 | awaiting T+20 | — | $2.21 (−28.94%) |
Oct 6, 2026 20d ago | 6-K | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 6, 2026 20d ago | Press Release | $3.09 | awaiting T+20 | — | $2.21 (−28.48%) |
Oct 5, 2026 21d ago | SC 13G/A | $3.27 | awaiting T+20 | — | $2.21 (−32.42%) |
Sep 24, 2026 4w ago | 6-K | $4.00 $2.27 | ▼ −43.25% | ▼ −42.83% | $2.21 (−44.75%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 17, 2026 5w ago | 6-K | $3.72 $2.71 | ▼ −27.15% | ▼ −28.36% | $2.21 (−40.59%) |
Sep 15, 2026 5w ago | 6-K | $3.46 $2.89 | ▼ −16.47% | ▼ −19.45% | $2.21 (−36.13%) |
Sep 1, 2026 7w ago | 6-K | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
Sep 1, 2026 7w ago | Press Release | $3.08 $3.60 | ▲ +16.88% | ▲ +17.21% | $2.21 (−28.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers